Haematologica · 2026
Pediatric-inspired therapy and blinatumomab consolidation improve outcomes in young adults with Philadelphia-like acute lymphoblastic leukemia.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Aldoss Ibrahim, Li Arthur, Knobler Diana, Agrawal Vaibhav, Pourhassan Hoda, Koller Paul, Othman Tamer, Al Malki Monzr M, Salhotra Amandeep, Sandhu Karamjeet, Ali Haris, Aribi Ahmed, Blackmon Amanda, Ball Brian, Amanam Idoroenyi, Otoukesh Salman, Lin Rick, Alvarenga Thiebaud Julio C, Park Sunmin, Khaled Samer, Tinajero Jose, Ngo Dat, Gu Zhaohui, Murphy Lindsey, Samara Yazeed, Afkhami Michelle, Artz Andrew, Becker Pamela, Nakamura Ryotaro, Stein Anthony, Forman Stephen, Marcucci Guido, Pullarkat Vinod
Аннотация
Philadelphia (Ph)-like acute lymphoblastic leukemia (ALL) is a high-risk subtype of B-cell ALL associated with poor response to induction chemotherapy, suboptimal measurable residual disease (MRD) clearance, and inferior survival outcomes compared to non-Phlike subtypes. We retrospectively analyzed 140 consecutive adult patients with Ph-like ALL treated at our institution. The median age was 33.5 years, and the majority harbored CRLF2 rearrangements (85%). IKZF1plus deletion and JAK mutations were identified in 26% and 37% of patients, respectively. The majority (75%) received pediatric-inspired regimens (PIR), which were associated with higher complete remission (CR) rates (p=0.034), reduced risk of relapse (p.